Emerging fungal pathogens in pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 3, 2007, Pages 199-204

  Sanchez, Alejandro ^a   Larsen, Robert ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Fungal infection; Fungal pathogens; Molds

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; PENTAMIDINE; POSACONAZOLE; RAVUCONAZOLE; TERBINAFINE; TRIAZOLE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACREMONIUM; ASPERGILLUS; CLINICAL FEATURE; CLINICAL STUDY; DISEASE PREDISPOSITION; FUNGAL VIRULENCE; FUSARIUM; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IN VITRO STUDY; IN VIVO STUDY; LUNG ASPERGILLOSIS; LUNG DISEASE; LUNG INFECTION; MORTALITY; MYCOSIS; NONHUMAN; PAECILOMYCES; PENICILLIUM MARNEFFEI; PETRIELLIDIUM BOYDII; PHYSICIAN; RECOMMENDED DRUG DOSE; REVIEW; SCEDOSPORIUM APIOSPERMUM; SCOPULARIOPSIS BREVICAULIS; TREATMENT PLANNING; TRICHOSPORON;

ANTIFUNGAL AGENTS; HUMANS; INCIDENCE; LUNG DISEASES, FUNGAL; WORLD HEALTH;

EID: 34247108058     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3280f6cedc     Document Type: Review

References (70)

1. Al Refai M, Duhamel C, Le Rochais JP, Icard P. Lung scedosporiosis: a differential diagnosis of aspergillosis. Eur J Cardiothorac Surg 2002; 21:938-939.
2. Koga T, Kitajima T, Tanaka R, et al. Chronic pulmonary scedosporiosis simulating aspergillosis. Respirology 2005; 10:682-685.
3. Steinbach WJ, Perfect JR, Schell WA, et al. In vitro analysis, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48:3217-3225.
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415.
5. Steinbach WJ, Benjamin DK, Kontoyiannis DP. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39:192-198.
6. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to head comparsion of the activities of currently available antufungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50:917-921. Presents one of the largest in-vitro antifungal susceptibility surveys of various antifungal agents to a wide range of fungal pathogens.
7. Lewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: a pharmacodynamic approach for the detection of combined antifungal activity in vitro. J Antimicrob Chemother 2005; 56:887-892.
8. Philip A, Odabasi Z, Rodriguez J, et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Apergillus spp. and Fusarium spp. Antimicrob Agents Chemother 2005; 49:3572-3574.
9. Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10(S1):67-74.
10. Gorman SR, Magiorakos AP, Zimmerman SK, Craven DE. Fusarium oxysporum pneumonia in an immunocompetent host. South Med J 2006; 99:613-616.
11. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest 1997; 112:1128-1130.
12. Pujol I, Guarro J, Gene J, Sala J. In vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother 1997; 39:163-167.
13. Cosigny S, Dhedin N, Datry A, et al. Successful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37:311-313.
14. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-1131.
15. Cudillo L, Girmenia C, Santilli S, et al. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005; 40:1212-1213.
16. Herbrecht R, Kessler R, Kravanja C, et al. Succesful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung tranpslant recipient. J Heart Lung Transplant 2004; 23:1451-1454.
17. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398-1403. Clinical data for the use of posaconazole for fusariosis.
18. Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother 2003; 47:3252-3259.
19. Lionakis MS, Chamilos G, Lewis RE, et al. Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. Antimicrob Agents Chemother 2006; 50:294-297.
20. Fernando SSE, Jones P, Vaz R. Fine needle aspiration of a pulmonary mycetoma. A case report and review of the literature. Pathology 2005; 37:322-324.
21. Palacio A, Garau M, Amor E, et al. Case reports: Transient colonization with Scedoporium prolificans. Report of four cases in Madrid. Mycoses 2001; 44:321-325.
22. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40:89-99.
23. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62-68.
24. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22:111-113.
25. Meletiadis J, Mouton JW, Meis FGM, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedoporium prolificans isolates. Antimicrob Agents Chemother 2003; 47:106-117.
26. Whyte M, Irving H, O'Regan P, et al. Disseminated Scedoporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J 2005; 24:375-377.
27. Heyn K, Tredup A, Salvenmoser S, Muller FMC. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005; 49:5157-5159.
28. Yustes C, Guarro J. In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp. Antimicrob Agents Chemother 2005; 49:3498-3500.
29. Bocanegra R, Najvar LK, Hernandez S, et al. Caspofungin and liposomal amphotericin B therapy of experimental murine scedosporiosis. Antimicrob Agents Chemother 2005; 49:5139-5141.
30. Herbrecht R, Letscher-Bru V, Fohrer C, et al. Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur J Clin Microbiol Infect Dis 2002; 21:814-817.
31. Mattei D, Mordini N, Nigro CL, et al. Successful treatment of Acremonium fungemia with voriconazole. Mycoses 2003; 46:511-514.
32. Miyakis S, Velegraki A, Delikou S, et al. Invasive Acremonium strictum infection in a bone marrow transplant recipient. Pediatr Infect Dis J 2006; 25:273-275. Includes a review of Acremonium infections in children.
33. Fenech FF, Malia CP. Pleural effusion caused by Penicillum lilacinum. Br J Dis Chest 1972; 66:284-290.
34. Ono N, Sato K, Yokomise K. Lung abscess caused by Paecilomyces lilacinus. Respiration 1999; 66:85-87.
35. Lee J, Yew WW, Chiu CS, et al. Delayed sternotomy wound infection due to Paecilomyces variotii in a lung transplant recipient. J Heart Lung Transplant 2002; 21:1131-1134.
36. Gutierrez F, Masia M, Ramos JM, et al. Lack of efficacy of voriconazole therapy in 2 patients with pulmonary fungus balls. Clin Infect Dis 2005; 40:1706-1707.
37. Gutierrez F, Masia M, Ramos JM, et al. Pulmonary mycetoma caused by an atypical isolate of Paecilomyces species in an immunocompetent individual: case report and literature review of Paecilomyces lung infections. Eur J Clin Microbiol Infect Dis 2005; 24:607-611.
38. Hara J, Fujimara M, Tachibana H, et al. A case of acute hypersensitivity pneumonitis associated with an oil fan heater. Am J Med Sci 2006; 331:35-36.
39. Cuenca-Estrella M, Gomez-Lopez A, Buitrago MJ, et al. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis. Antimicrob Agents Chemother 2006; 50:2248-2250. Data on in-vitro antifungal combination therapy against Scopulariopsis.
40. Ortoneda M, Capilla J, Pastor FJ, et al. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother 2004; 48:2727-2729.
41. Endo S, Hironaka M, Murayama F, et al. Scopulariopsis fungus ball. Ann Thorac Surg 2002; 74:926-927.
42. Chen-Scarabelli C, Scarabelli TM. Fungal endocarditis due to Scopulariopsis. Ann Intern Med 2003; 139:W77.
43. Nwabuisi C, Salami AK, Abdullahi NA, Agbede OO. Scopulariopsis associated meningitis in adult Nigerian AIDS patient: a case report. West Afr J Med 2003; 22:364-365.
44. Isidro AM, Amorosa V, Stopyra GA, et al. Fungal prosthetic valve endocarditis caused by Scopulariopsis species: case report and review of the literature. J Thorac Cardiovasc Surg 2006; 131:1181-1183.
45. Mohammedi I, Piens MA, Valette CA, et al. Fatal Microascus trigonosporus (Anamorph Scopulariopsis) pneumonia in a bone marrow transplant recipient. Eur J Clin Microbiol Infect Dis 2004; 23:215-217.
46. Wagner D, Sander A, Bertz H, et al. Breakthrough invasive infection due to Debaryomyces hansenii and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 2005; 33:397-400.
47. Wuyts WA, Molzahn H, Maertens J, et al. Fatal Scopulariopsis infection in a lung transplant recipient: a case report. J Heart Lung Transplant 2005; 24:2301-2304.
48. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Scopulariopsis brevicaulis, a fungal pathogen resistant to broad-spectrum antifungal agents. Antimicrob Agents Chemother 2003; 47:2339-2341.
49. Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43:1818-1828.
50. Matsunaga Y, Usui Y, Yoshizawa Y. TA-19, a novel protein antigen of Trichosporon asahii, in summer-type hypersensitivity pneumonitis. Am J Respir Crit Care Med 2003; 167:991-998.
51. Sugita T, Ikeda R, Nishikawa A. Analyis of Trichosporon isolates obtained from the houses of patients with summer-type hypersensitivity pneumonitis. J Clin Microbiol 2004; 42:5467-5471.
52. Fournier S, Pavageau W, Feuillhade M, et al. Use of voriconazole to successfully treat disseminated Trischosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Microbiol Infect Dis 2002; 21:892-896.
53. Matsue K, Uryu H, Koseki M, et al. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 2006; 42:753-757. 4 case reports of breakthrough infections with micafungin; providing some caution on the use of this class of antifungal for the treatment of trichosporonosis.
54. Paphitou NI, Ostrosky-Zeichner L, Paetnick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46:1144-1146.
55. Rodriguez-Tudela JL, Diaz-Guerra TM, Mellado E, et al. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob Agents Chemother 2005; 49:4026-4034.
56. Antachopoulos C, Papakonstantinou E, Dotis J, et al. Fungemia due to Trichosporon asahii in a neutropenic child refractory to amphotericin B: clearance with voriconazole. J Pediatr Hematol Oncol 2005; 27:283-285.
57. Asada N, Uryu H, Koseki M, et al. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 2006; 43:e39-e41. Case report of the successful use of voriconazole for the treatment of T. asahii.
58. Vanittanakom N, Cooper CR, Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular aspects. Clin Microbiol Rev 2006; 19:95-110. A very thorough overview of P. marneffei.
59. DiSalvo AF, Fickling AM, Ajello L. Infection caused by Penicillium marneffei: description of first natural infection in man. Am J Clin Pathol 1973; 60:259-263.
60. Lu PX, Zhu WK, Liu Y, et al. Acquired immunodeficiency syndrome associated disseminated Penicillium marneffei infection: report of 8 cases. Chin Med J 2005; 118:1395-1399.
61. Woo PCY, Lau SKP, Lau CCY, et al. Penicillium marneffei fungemia in an allogenic bone marrow transplant recipient. Bone Marrow Transplant 2005; 35:831-833.
62. Deesomchok A, Tamprawate S. A 12-case series of Penicillium marneffei pneumonia. J Med Assoc Thai 2006; 89:441-447. An excellent review for the pulmonogist on Penicillium pneumonia characteristics.
63. Mootsikapun P, Srikulbutr S. Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings, and outcome. Int J Infect Dis 2006; 10:66-71.
64. Zhiyong Z, Mei K, Yanbin L. Disseminated Penicillium marneffei infection with fungemia and endobronchial disease in an AIDS patient in China. Med Princ Pract 2006; 15:235-237.
65. Sun HY, Chen MY, Hsiao CF, et al. Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus with highly active-retroviral therapy. Clin Microbiol Infect 2006; 12:381-388.
66. Lee YM, Kim YK, Kim SO, et al. A case of hypersensitivity pneumonitis caused by Penicillium species in a home environment. J Korean Med Sci 2005; 20:1073-1075.
67. Lim D, Lee YS, Chang AR. Rapid diagnosis of Penicillium marneffei infection by fine needle aspiration cytology. J Clin Pathol 2006; 59:443-444. An alternative approach for rapid diagnosis utilizing histological patterns.
68. Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicllium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993; 37:2407-2411.
69. Filiotou A, Velegraki A, Giannaris M, et al. First case of Penicillium marneffei fungemia in Greece and strain susceptibility to five licensed systemic antifungal agents and posaconazole. Am J Med Sci 2006; 332:43-45. A representative case of imported Penicillium marneffei infection.
70. Skoulidis F, Morgan MS, MacLeod KM. Penicillium marneffei: a pathogen on our doorstep? J R Soc Med 2004; 97:394-396.